Thomas R. Insel

Last updated
Thomas Roland Insel [1]
Thomas Insel NIMH 2011.JPG
Born (1951-10-19) October 19, 1951 (age 70)
Alma mater Boston University (B.A.)
Boston University (M.D.)
Known forResearch on oxytocin and vasopressin and their impact on social behavior
Scientific career
Institutions National Institute of Mental Health
Emory University
Notes
Paul A. Insel (brother)

Thomas Roland Insel (born October 19, 1951) is an American neuroscientist, psychiatrist, entrepreneur, and author who led the National Institute of Mental Health (NIMH) from 2002 until November 2015. [2] Prior to becoming Director of NIMH, he was the founding Director of the Center for Behavioral Neuroscience at Emory University in Atlanta, Georgia. [3] [4] He is best known for research on oxytocin and vasopressin, two peptide hormones implicated in complex social behaviors, such as parental care and attachment. [5] [6] He announced on Sept. 15, 2015, that he was resigning as the director of the NIMH to join the Life Science division of Google X (now Verily Life Sciences). [7] On May 8, 2017, CNBC reported that he had left Verily Life Sciences. [8] Insel is a Co-founder with Richard Klausner and Paul Dagum of a digital mental health company named "Mindstrong," [9] a Bay-area startup. He has also co-founded Humanest Care, NeuraWell Therapeutics, and MindSite News and is a member of the scientific advisory board for Compass Pathways, a company that is developing the psychedelic drug psilocybin to treat depression and other mental health disorders. His book, Healing: Our Path from Mental Illness to Mental Health was published by Penguin Random House in February, 2022.

Contents

Early years

Born in Dayton, Ohio, Insel was the youngest of four sons. His father, H. Herbert Insel, was an ophthalmologist who moved the family from Ohio to Silver Spring, Maryland in 1960. There, the precocious Insel earned his Eagle Scout badge just after turning 13, began college courses at age 14 and left high school to enroll in the Boston University Combined Pre-Med- Medical Program, where he focused on English literature, at age 15. By age 17, having completed most of the requirements for his pre-medical degree and still below draft age, Insel began exploring the world. He hitch-hiked across Canada and through the West, married Deborah Silber soon after his 18th birthday, then traveled with her around the world, stopping to work at a TB clinic in Hong Kong and a mission hospital in Bihar, India.

From 1970-1974 Insel attended Boston University Medical School with plans to return to Asia working in tropical medicine. These plans changed with exposure to two prominent Boston neuroscientists: Walle Nauta at MIT and Norman Geschwind at Harvard Medical School. Following medical school, he trained in psychiatry at University California San Francisco (1976-1979) including in Jungian psychoanalysis and a first exposure to research with Irwin Feinberg.

Research career

Following clinical training, Insel joined the NIMH as a clinical fellow working with Dennis Murphy. In 1980 he began the first U.S. research project on the biology of adults with obsessive compulsive disorder (OCD), which was then largely treated with psychoanalysis. Following initial reports from Sweden, Insel was the first to demonstrate scientifically that a tricyclic antidepressant, clomipramine, was effective for treating OCD. This observation not only launched the neuropharmacological study of OCD, it suggested the importance of developing the SSRI class of antidepressants, which became a mainstay for treating both depression and OCD in the 1990s.

Following this foray into clinical research, Insel moved from the clinic into the laboratory to study the neurobiology of emotion. Beginning in the NIMH Laboratory of Brain Evolution and Behavior started by Paul Maclean in Poolesville, MD, his group developed some of the classic studies for investigating social behavior in animals, from ultrasonic vocalizations in rodent pups to social attachment in prairie voles to paternal care in marmosets. A major focus was oxytocin, known to support lactation and parturition, but shown in rats to be important for the initiation of maternal care by actions on brain receptors. Oxytocin and the related hormone vasopressin were also found to be critical for pair bonding in adult prairie voles. The Insel lab found that monogamous voles and non-monogamous voles (that did not pair bond) had brain receptors for oxytocin and vasopressin in different brain circuits, suggesting a mechanism for the evolution of monogamy in mammals.[ citation needed ]

In 1994 Insel was recruited to Emory University to direct the Yerkes Regional Primate Research Center, the nation's oldest and internationally one of the largest centers for research on monkeys and great apes. His tenure at Yerkes was marked by a focus on neurobiology and infectious disease, with a specific emphasis on development of an AIDS vaccine. This was also a period of considerable animal rights protests against Yerkes, with Insel and his family targeted by protesters opposed to invasive research with non-human primates.

In 1999 Insel resigned from Yerkes to lead a new $40 million National Science Foundation Science and Technology Center, the Center for Behavioral Neuroscience. This new program used behavioral neuroscience to develop a cross-institutional training and research effort for 7 colleges and universities in Atlanta, with a specific goal of increasing the number of African American undergraduate students participating in neuroscience research. This period was also a productive phase for social neuroscience research carried out at Emory. Larry Young, Zuoxin Wang, and Jim Winslow and several outstanding graduate students focused on the molecular biology, anatomy, and behavioral properties of oxytocin and vasopressin, providing critical evidence for the role of these neuropeptide systems in complex social behaviors. In his final years at Emory Insel led the team into studies of autism, starting a new NIH funded Autism Center to investigate oxytocin and vasopressin as potential treatments for this disorder of social behavior.

NIMH director

Insel's return to become the ninth director of NIMH in 2002 was unexpected, as he had little connection to academic psychiatry or psychology since his OCD research which ended almost twenty years before. At NIMH he quickly focused on serious mental illnesses, such as schizophrenia, bipolar illness, and major depressive disorder with a defining theme of these illnesses as disorders of brain circuits. Building on the genomics revolution, he created large repositories of DNA and funded many of the first large genotyping and sequencing efforts to identify risk genes. He established autism as a major area of focus for NIMH and led a large increase of NIH funding for autism research. Under his leadership, autism, as a developmental brain disorder, became a prototype for mental disorders, most of which also emerge during development. And during his tenure, NIMH became a leader in global mental health, working closely with the World Health Organization and the Global Alliance for Chronic Disease.

Private sector

In December, 2015, Dr. Insel joined Verily, a health technology start-up emerging from Google X. At Verily, he founded and led the mental health team with a focus on digital phenotyping, using smartphone signals for measuring behavior and mood. In May 2017, Dr. Insel moved to Mindstrong, based in Palo Alto, California, as the startup's President and Co-Founder. [10] Mindstrong created measurement-based care solutions, especially for people with serious mental illness. In 2019, he took a leave of absence from Mindstrong to assist newly elected California Governor Gavin Newsom on a reorganization of the state's behavioral healthcare system. Newsom named Dr. Insel as his "behavioral health czar" although he served only as a volunteer in this role. He simultaneously served as Chair of the Board for the Steinberg Institute, a behavioral health policy shop in Sacramento, California. In early 2020, Dr. Insel returned to the private sector with a new mental health start-up, NEST Health renamed Humanest Care, co-founded with his daughter, Lara Gregorio. His book, Healing: Our Path from Mental Illness to Mental Health, about transforming behavioral health is in press with Penguin Random House, with publication planned for February, 2022. In 2021, Dr. Insel co-founded a non-profit, digital publication MindSite News to focus on the intersection of mental health and social justice issues. He currently serves on the boards of Fountain House, Foundation for NIH, Steinberg Institute, and the Schaeffer Center for Health Policy and Economics as well as serving as an advisor for several innovative mental health companies (Alto Neuroscience, Cerebral, Compass Pathways, Embodied, Koa Health, NeuraWell Therapeutics, Owl Insights, PsychHub, Uplift Health, Valera Health).

Recognition

Insel is a member of the National Academy of Medicine, National Academy of Sciences.[6] He has received the A.E. Bennett Award (1986), the Curt Richter Prize (1991), the Outstanding Service Award from the US Public Health Service (1993), the Sachar Prize (2007), the Outstanding Alumnus Award from Boston University (2009), the NAMI Outstanding Service Award (2009), the IPSEN Prize (2010), the Shorr Family Prize from the University of Arizona (2011), the Dr. Nathan Davis Award for Government Service from the American Medical Association (2013), the Jed Foundation Voice of Mental Health Award (2013), the American Psychiatric Nurses Association 2013 Scientific Partnership Award, the Brain & Behavior Research Foundation ‘Productive Lives’ Award (2014), the Child Mind Institute Distinguished Scientist Award (2014), and the Autism Science Foundation Distinguished Scientist Award (2015). Insel has received honorary degrees from the University of Edinburgh (2014), the Feinstein Institute of Medical Research (2016), University of Basel (2018), Boston University (2020). His work has been cited with features in the New York Times and The Atlantic and Wall Street Journal

Publications

In addition to over 200 published scientific articles or chapters, books by Insel include:

Related Research Articles

Vasopressin Mammalian hormone released from the pituitary gland

Human vasopressin, also called antidiuretic hormone (ADH), arginine vasopressin (AVP) or argipressin, is a hormone synthesized from the AVP gene as a peptide prohormone in neurons in the hypothalamus, and is converted to AVP. It then travels down the axon terminating in the posterior pituitary, and is released from vesicles into the circulation in response to extracellular fluid hypertonicity (hyperosmolality). AVP has two primary functions. First, it increases the amount of solute-free water reabsorbed back into the circulation from the filtrate in the kidney tubules of the nephrons. Second, AVP constricts arterioles, which increases peripheral vascular resistance and raises arterial blood pressure.

Oxytocin Peptide hormone and neuropeptide

Oxytocin is a peptide hormone and neuropeptide normally produced in the hypothalamus and released by the posterior pituitary. It plays a role in social bonding, reproduction, childbirth, and the period after childbirth. Oxytocin is released into the bloodstream as a hormone in response to sexual activity and during labour. It is also available in pharmaceutical form. In either form, oxytocin stimulates uterine contractions to speed up the process of childbirth. In its natural form, it also plays a role in bonding with the baby and milk production. Production and secretion of oxytocin is controlled by a positive feedback mechanism, where its initial release stimulates production and release of further oxytocin. For example, when oxytocin is released during a contraction of the uterus at the start of childbirth, this stimulates production and release of more oxytocin and an increase in the intensity and frequency of contractions. This process compounds in intensity and frequency and continues until the triggering activity ceases. A similar process takes place during lactation and during sexual activity.

National Institute of Neurological Disorders and Stroke Department of the U.S. National Institutes of Health

The National Institute of Neurological Disorders and Stroke (NINDS) is a part of the U.S. National Institutes of Health (NIH). It conducts and funds research on brain and nervous system disorders and has a budget of just over US$2.03 billion. The mission of NINDS is "to reduce the burden of neurological disease—a burden borne by every age group, every segment of society, and people all over the world". NINDS has established two major branches for research: an extramural branch that funds studies outside the NIH, and an intramural branch that funds research inside the NIH. Most of NINDS' budget goes to fund extramural research. NINDS' basic science research focuses on studies of the fundamental biology of the brain and nervous system, genetics, neurodegeneration, learning and memory, motor control, brain repair, and synapses. NINDS also funds clinical research related to diseases and disorders of the brain and nervous system, e.g. AIDS, Alzheimer's disease, epilepsy, muscular dystrophy, multiple sclerosis, Parkinson's disease, spinal cord injury, stroke, and traumatic brain injury.

The National Institute of Mental Health (NIMH) is one of 27 institutes and centers that make up the National Institutes of Health (NIH). The NIH, in turn, is an agency of the United States Department of Health and Human Services and is the primary agency of the United States government responsible for biomedical and health-related research.

Paul D. MacLean

Paul Donald MacLean was an American physician and neuroscientist who made significant contributions in the fields of physiology, psychiatry, and brain research through his work at Yale Medical School and the National Institute of Mental Health. MacLean's evolutionary triune brain theory proposed that the human brain was in reality three brains in one: the reptilian complex, the limbic system, and the neocortex.

David Gil Amaral is a professor of psychiatry at the University of California, Davis, United States, and since 1998 has been the research director at the M.I.N.D. Institute, an affiliate of UC Davis, engaged in interdisciplinary research into the causes and treatment of autism and related neurodevelopmental disorders. Amaral joined the UC Davis faculty as a Professor in the Department of Psychiatry and the Center for Neuroscience and as an investigator at the California Regional Primate Research Center in 1991. Since 1995, he has been a professor of psychiatry in the UC Davis School of Medicine, with an appointment to the Center for Neuroscience.

High-functioning autism (HFA) is an autism classification where a person exhibits no intellectual disability, but may exhibit deficits in communication, emotion recognition and expression, and social interaction. HFA is not included in either the American Psychological Association's DSM-5 or the World Health Organization's ICD-10, neither of which subdivides autism based on intellectual capabilities.

Vasopressin receptor 1A Protein-coding gene in the species Homo sapiens

Vasopressin receptor 1A (V1AR), or arginine vasopressin receptor 1A is one of the three major receptor types for vasopressin, and is present throughout the brain, as well as in the periphery in the liver, kidney, and vasculature.

Steven Edward Hyman is Director of the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard in Cambridge, Massachusetts. He is also Harvard University Distinguished Service Professor of Stem Cell and Regenerative Biology. Hyman was Provost of Harvard University from 2001 to 2011 and before that Director of the U.S. National Institute of Mental Health (NIMH) from 1996 to 2001. Hyman received the 2016 Rhoda and Bernard Sarnat International Prize in Mental Health from the National Academy of Medicine for "leadership in furthering understanding and treatment of psychiatric disorders as biological diseases".

C. Sue Carter American biologist and behavioral neurobiologist

C. Sue Carter is an American biologist and behavioral neurobiologist. She is an internationally recognized expert in behavioral neuroendocrinology. In 2014 she was appointed Director of The Kinsey Institute and Rudy Professor of Biology at Indiana University. Carter was the first person to identify the physiological mechanisms responsible for social monogamy.

Susan Swedo is a researcher in the field of pediatrics and neuropsychiatry. Beginning in 1998, she was Chief of the Pediatrics & Developmental Neuroscience Branch at the US National Institute of Mental Health. In 1994, Swedo was lead author on a paper describing pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS), a controversial hypothesis proposing a link between Group A streptococcal infection in children and some rapid-onset cases of obsessive-compulsive disorder (OCD) or tic disorders such as Tourette syndrome. Swedo retired from the NIH in 2019, and serves on the PANDAS Physician Network.

Sarah Lisanby American medical researcher

Sarah H. Lisanby is an American psychiatrist who studies the use of neurostimulation devices to treat mental illness. Since 2015 she has directed the division of the National Institute of Mental Health(NIMH) working on translational research.

Gerald Fischbach American physician and neuroscientist (born 1938)

Gerald D. Fischbach is an American neuroscientist. He received his M.D. from the Weill Cornell Medical College of Cornell University in 1965 before beginning his research career at the National Institutes of Health in 1966, where his research focused on the mechanisms of neuromuscular junctions. After his tenure at the National Institutes of Health, Fischbach was a professor at Harvard University Medical School from 1972–1981 and 1990–1998 and the Washington University School of Medicine from 1981–1990. In 1998, he was named the director of the National Institute of Neurological Disorders and Stroke before becoming the Vice President and Dean of the Health and Biomedical Sciences, the Dean of the Faculty of Medicine, and the Dean of the Faculty of Health Sciences at Columbia University from 2001–2006. Gerald Fischbach currently serves as the scientific director overseeing the Simons Foundation Autism Research Initiative. Throughout Fischbach's career, much of his research has focused on the formation and function of the neuromuscular junction, which stemmed from his innovative use of cell culture to study synaptic mechanisms.

Research Domain Criteria Diagnostic framework in personalized psychiatry

The Research Domain Criteria (RDoC) project is an initiative of personalized medicine in psychiatry developed by US National Institute of Mental Health (NIMH). In contrast to the Diagnostic and Statistical Manual of Mental Disorders (DSM) maintained by the American Psychiatric Association (APA), RDoC aims to address the heterogeneity in the current nosology by providing a biologically-based, rather than symptom-based, framework for understanding mental disorders. "RDoC is an attempt to create a new kind of taxonomy for mental disorders by bringing the power of modern research approaches in genetics, neuroscience, and behavioral science to the problem of mental illness."

Susan Amara American neuroscientist

Susan G. Amara is an American professor of neuroscience and is the Scientific Director of the National Institute of Mental Health. Dr. Amara is an elected member of the National Academy of Sciences and a fellow of the American Association for the Advancement of Science. She is a Past-President of the Society for Neuroscience. Dr. Amara has a B.S. in Biological Sciences from Stanford University and a Ph.D. in Physiology and Pharmacology from the University of California, San Diego.

Judith L. Rapoport American psychiatrist

Judith L. Rapoport is an American psychiatrist. She is the chief of the Child Psychiatry Branch at the National Institute of Mental Health (NIMH), part of the National Institutes of Health (NIH) in Bethesda, Maryland.

Daniel R. Weinberger is a professor of psychiatry, neurology and neuroscience at Johns Hopkins University and Director and CEO of the Lieber Institute for Brain Development, which opened in 2011.

Larry J. Young

Larry J. Young is the William P. Timmie Professor of Psychiatry and Behavioral Sciences at the School of Medicine at Emory University. Dr. Young studies how genetic, cellular and neurobiological mechanisms regulate complex social behavior, including social cognition and social bonding. His research focuses heavily on the roles of the neuropeptides oxytocin and vasopressin in regulating the neural processing of social signals and social attachment.

Dominick P. Purpura

Dominick P. Purpura was a neuroscientist. who was well known for his research focused on intellectual disability. His work also focused on the origin of brain waves, developmental neurobiology, and epilepsy. From 1982 to 1983, Purpura was appointed as the president of the Society for Neuroscience. In 1984, he was recruited to be the dean of Albert Einstein College of Medicine of Yeshiva University. He served as the dean for a total of 22 years.

Bryan L. Roth is the Michael Hooker Distinguished Professor of Protein Therapeutics and Translational Proteomics, University of North Carolina School of Medicine. He is recognized for his discoveries and inventions in the general areas of molecular pharmacology, GPCR structure, and function and synthetic neurobiology. He is a member of the American Academy of Arts and Sciences (AAAS) and the National Academy of Medicine of the National Academy of Sciences (NAM)

References

  1. "Medical Board of California Licensing Details for G 30484 - Insel, Thomas Roland". California Department of Consumer Affairs License Search Results. California DCA. Retrieved 30 Dec 2019.
  2. Insel, Thomas R. (29 October 2015). "Post by Former NIMH Director Thomas Insel: Farewell". Blog Posts by Thomas Insel (Blog). NIMH. Retrieved 13 May 2017.
  3. "Washington in Brief" . The Washington Post . 11 September 2002. p. A.05. Retrieved 13 May 2017.
  4. "Thomas R. Insel, M.D." University of Michigan Depression Center. University of Michigan. Archived from the original on 29 August 2004.
  5. "At NIMH, Outgrowing Jung Ideas; New Chief to Focus Studies On Genes and Neurobiology "The Washington Post Nov 13, 2002.
  6. "NIMH · Publications". Archived from the original on 2009-06-20. Retrieved 2012-12-11.
  7. "NIH Director?s Statement Regarding Dr. Thomas Insel?s Departure - the NIH Director - National Institutes of Health (NIH)". Archived from the original on 2015-09-18. Retrieved 2015-09-15.
  8. "Another high-profile departure for Alphabet's 'Other Bets': Thomas Insel leaves Verily". CNBC . 8 May 2017.
  9. "Former Director of the National Institute of Mental Health, Dr. Thomas Insel, Joins Mindstrong Health as President and Co-Founder". Market Wired. 11 May 2017. Retrieved 1 February 2018.
  10. "Former Director of the National Institute of Mental Health, Dr. Thomas Insel, Joins Mindstrong Health as President and Co-Founder". Market Wired. 11 May 2017. Retrieved 1 February 2018.